G. Pignot

Risk Stratification in Non-Muscle-Invasive Bladder Cancer in the Era of Expanding Therapeutic Options: Are Current Classifications Still Adequate?

BACKGROUND NMIBC risk classifications from AFU, EAU, AUA/SUO and NCCN were derived decades ago to estimate recurrence and progression, but the therapeutic landscape has since expanded, gene therapy, an IL-15 superagonist, systemic immunotherapy, and BCG-combination regimens, raising the question of whether these classi...